[go: up one dir, main page]

SV2011003919A - Extrudidos con sustancias activas con forma de agujas - Google Patents

Extrudidos con sustancias activas con forma de agujas

Info

Publication number
SV2011003919A
SV2011003919A SV2011003919A SV2011003919A SV2011003919A SV 2011003919 A SV2011003919 A SV 2011003919A SV 2011003919 A SV2011003919 A SV 2011003919A SV 2011003919 A SV2011003919 A SV 2011003919A SV 2011003919 A SV2011003919 A SV 2011003919A
Authority
SV
El Salvador
Prior art keywords
needles
extruded
active substances
active substance
pharmaceutically active
Prior art date
Application number
SV2011003919A
Other languages
English (en)
Inventor
Venkata-Rangarao Kanikanti
Hans-Juergen Hamann
Peter Kleinebudde
Rieke Witzleb
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41785839&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2011003919(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of SV2011003919A publication Critical patent/SV2011003919A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCIÓN SE REFIERE A EXTRUDIDOS QUE CONTIENEN AL MENOS UNA SUSTANCIA FARMACÉUTICAMENTE ACTIVA EN FORMA DE AGUJAS, DONDE LA RELACIÓN ENTRE EL TAMAÑO DE PARTÍCULAS DE LA SUSTANCIA FARMACÉUTICAMENTE ACTIVA CON FORMA DE AGUJAS Y EL DIÁMETRO DE LA CADENA ES DE AL MENOS 1:15, Y AL USO DE ESTOS EXTRUDIDOS PARA LA PRODUCCIÓN DE MEDICAMENTOS
SV2011003919A 2008-12-05 2011-05-26 Extrudidos con sustancias activas con forma de agujas SV2011003919A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102008060472 2008-12-05

Publications (1)

Publication Number Publication Date
SV2011003919A true SV2011003919A (es) 2011-08-28

Family

ID=41785839

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2011003919A SV2011003919A (es) 2008-12-05 2011-05-26 Extrudidos con sustancias activas con forma de agujas

Country Status (27)

Country Link
US (1) US20120034273A1 (es)
EP (1) EP2373287B1 (es)
JP (2) JP5860284B2 (es)
KR (1) KR20110096145A (es)
CN (1) CN102238940B (es)
AR (1) AR075106A1 (es)
AU (1) AU2009321822B2 (es)
BR (1) BRPI0922302B8 (es)
CA (1) CA2745456A1 (es)
CL (1) CL2011001207A1 (es)
CO (1) CO6440550A2 (es)
CR (1) CR20110285A (es)
DO (1) DOP2011000160A (es)
EC (1) ECSP11011080A (es)
ES (1) ES2685472T3 (es)
IL (1) IL212846A0 (es)
MX (1) MX2011005572A (es)
NI (1) NI201100103A (es)
NZ (1) NZ593217A (es)
PE (1) PE20120182A1 (es)
RU (1) RU2549450C2 (es)
SV (1) SV2011003919A (es)
TW (1) TWI522114B (es)
UA (1) UA105648C2 (es)
UY (1) UY32287A (es)
WO (1) WO2010063387A1 (es)
ZA (1) ZA201104145B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU231017B1 (hu) * 2012-05-08 2019-11-28 LAVET Gyógyszeripari Kft. Praziquantel tartalmú ízfedett formulációk
EP2968569A4 (en) 2013-03-15 2016-11-02 Argenta Mfg Ltd COUGAR FORMULATION
WO2015071668A1 (en) * 2013-11-14 2015-05-21 Cipla Limited Pharmaceutical compositions
CA3049952A1 (en) 2017-07-26 2019-01-31 Tgx Soft Chew, Llc Starch-free soft chew for veterinary applications
CA3191671A1 (en) 2020-09-04 2022-03-10 Elanco Us Inc. Palatable formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4402752B2 (ja) * 1997-05-19 2010-01-20 大日本住友製薬株式会社 免疫増強製剤
IT1298574B1 (it) * 1998-02-06 2000-01-12 Vectorpharma Int Composizioni farmaceutiche in forma di microparticelle a base polimerica ottenute mediante estrusione e sferonizzazione
DE19916383A1 (de) * 1999-03-31 2000-10-05 Schering Ag Pharmazeutische Zusammensetzung mit einem Extrusionsstoff
US7914818B2 (en) * 2001-08-06 2011-03-29 Purdue Pharma L.P. Opioid agonist formulations with releasable and sequestered antagonist
CA2489295A1 (en) * 2002-06-27 2004-01-08 Cilag Ag Spherical pellet containing a water-soluble active ingredient
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
EP1841414A1 (en) * 2003-12-31 2007-10-10 Alpharma, Inc. Rosiglitazone and metformin formulations
DK1566173T3 (da) * 2004-02-20 2006-12-27 Mattern Udo Farmaceutisk sammensætning til oral anvendelse og fremgangsmåde til fremstilling deraf
EP1690528A1 (de) * 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
JPWO2006090640A1 (ja) * 2005-02-23 2008-07-24 太陽化学株式会社 アミノ酸含有錠剤組成物および錠剤の製造方法
DE102005062270A1 (de) * 2005-12-24 2007-06-28 Bayer Technology Services Gmbh Geschmacksmaskierung von Pulvern
AU2007322269A1 (en) * 2006-10-11 2008-05-29 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
DE102007026550A1 (de) * 2007-06-08 2008-12-11 Bayer Healthcare Ag Extrudate mit verbesserter Geschmacksmaskierung
CN101590020B (zh) * 2008-05-30 2012-02-08 上海新菲尔生物制药工程技术有限公司 一种对氨基水杨酸钠结肠定位给药系统

Also Published As

Publication number Publication date
NI201100103A (es) 2012-04-16
CL2011001207A1 (es) 2011-10-28
ECSP11011080A (es) 2011-06-30
EP2373287A1 (de) 2011-10-12
DOP2011000160A (es) 2011-06-30
PE20120182A1 (es) 2012-02-24
CN102238940A (zh) 2011-11-09
AU2009321822B2 (en) 2015-04-16
CA2745456A1 (en) 2010-06-10
EP2373287B1 (de) 2018-05-30
RU2549450C2 (ru) 2015-04-27
UA105648C2 (uk) 2014-06-10
JP5860284B2 (ja) 2016-02-16
HK1163547A1 (en) 2012-09-14
TWI522114B (zh) 2016-02-21
AU2009321822A1 (en) 2011-06-30
BRPI0922302A2 (pt) 2016-01-05
ES2685472T3 (es) 2018-10-09
BRPI0922302B8 (pt) 2021-05-25
CO6440550A2 (es) 2012-05-15
RU2011127248A (ru) 2013-01-10
US20120034273A1 (en) 2012-02-09
NZ593217A (en) 2013-05-31
JP2012510956A (ja) 2012-05-17
CR20110285A (es) 2011-09-27
IL212846A0 (en) 2011-07-31
MX2011005572A (es) 2011-06-16
BRPI0922302B1 (pt) 2020-09-15
CN102238940B (zh) 2014-07-30
JP2015134812A (ja) 2015-07-27
UY32287A (es) 2010-06-30
KR20110096145A (ko) 2011-08-29
ZA201104145B (en) 2012-09-26
WO2010063387A1 (de) 2010-06-10
AR075106A1 (es) 2011-03-09
TW201031422A (en) 2010-09-01

Similar Documents

Publication Publication Date Title
AR115939A2 (es) Composición que contiene palmitoil-etanolamida ultra-micronizada
CL2011000935A1 (es) Composicion farmaceutica que comprende acetaminofeno y un material de tramadol complejo, que exhibe una liberacion sostenida y coordinada a traves de una capa de liberacion sostenida y otra de liberacion inmediata; metodo de preparacion;y el uso de un material complejo de tramadol y acetaminofeno para preparar un medicamento para el tratamiento del dolor.
SV2009002858A (es) Nueva forma polimorfica y la forma amorfa de 5- cloro-n-([(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il]-metil)-2-tiofenocarboxamida
EA201400173A1 (ru) Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
ES2586135T3 (es) Formulaciones para el suministro oral de adsorbentes en el intestino
CL2014000759A1 (es) Composicion para uso en el crecimiento del cerebro y/o desarrollo cognitivo y/o desarrollo psicomotor que comprende al menos un ácido graso poliinsaturado de cadena larga (lc-pufa), al menos un probiótico y una mezcla de oligosacáridos; uso de la composición.
EA200700340A1 (ru) Мультичастицы
PE20140255A1 (es) Tableta dispersable en forma oral
CL2012000319A1 (es) Uso de una composición farmaceutica que comprende treprostinil para la preparación de un medicamento para el tratamiento o la prevención de una afección asociada a la fibrosis quística.
AR082688A1 (es) Uso de aglomerantes para preparar formulaciones estables al almacenamiento
CL2011000214A1 (es) Composicion farmaceutica que comprende progesterona micronizada y aceite de cartamo tipo ii; y uso para el tratamiento de una condicion relacionada con la insuficiencia de secrecion de progesterona.
CL2012000392A1 (es) Uso de un anticuerpo anti-cd20 afucosilado con una cantidad de fucosa de 60% o menos para tratar cancer en combinacion con fludarabina .
CL2016000008A1 (es) Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
SV2011003919A (es) Extrudidos con sustancias activas con forma de agujas
CL2008000610A1 (es) Composicion en forma de dosificacion transdermica o transmucosa que comprende una relacion en peso de buprenorfina a naloxona entre 2,1:1 y 8:1, util para el tratamiento del dolor.
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
GT200900287A (es) Extrudidos con enmascaramiento del sabor mejorado
CL2016001094A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
CL2013003700A1 (es) Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico.
AR068368A1 (es) Formas solidas de dosificacion de azitromicina de liberacion controlada
CL2012003119A1 (es) Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre.
CL2013000335A1 (es) Forma altamente cristalina de valsartan; proceso para prepararla; composicion farmaceutica que la comprende y uso en el tratamiento de la hipertension.
CL2008001477A1 (es) Composicion farmaceutica compuesta por la combinacion sinergica de un agente anticonvulsivante como gabapentina y un agente antiinflamatorio no esteroideo como meloxicam, los rangos de concentracion presentes para la gabapentina son 3 a 300 mg y de 0,1 a 30 mg para meloxicam; y uso para tratar el dolor neuropatico
AR065068A1 (es) Composicion farmaceutica que comprende tramadol y ketoprofeno en asociacion
AR081400A1 (es) Una composicion farmaceutica de liberacion controlada de losartan